Clinical Trials

LymphoidOther hematologic neoplasmPlasma cell

20 enrolled

Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04231877 2026-03-03

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

56 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05432635 2026-02-23

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT06227026 2026-02-17

PRODIGY

10 enrolled

Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06191887 2026-02-13

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

27 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04067414 2026-02-11

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

12 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04850495 2026-02-06

Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

Phase 1 Suspended

38 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05694364 2026-02-06

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

3 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04323956 2026-02-02

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

50 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04545762 2026-01-14

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

36 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03884998 2025-12-30

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

27 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT06208735 2025-12-15

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

24 enrolled

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03479268 2025-11-26

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

18 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

NCT03259503 2025-11-10

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

50 enrolled

Phase 1 Not yet recruiting

Hodgkin Disease, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01479842 2025-10-15

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

48 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02153580 2025-10-06

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

37 enrolled

Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

NCT05359211 2025-09-15

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

28 enrolled

Phase 1 Enrolling by invitation

Lymphoma, Large B-Cell, Diffuse

NCT07168486 2025-09-11

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

Lymphoma, Follicular, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02992522 2025-09-09

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

22 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04007029 2025-09-05

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

24 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03150329 2025-09-03

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

52 enrolled 13 charts

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04464200 2025-08-24

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

30 enrolled

Burkitt Lymphoma, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT05836896 2025-08-24

CARLOTTA01

16 enrolled

LymphoidPlasma cell

Multiple Myeloma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT05934838 2025-08-15

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Phase 1 Enrolling by invitation

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT06827782 2025-08-15

Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma

42 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06859008 2025-08-05

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

37 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06977711 2025-08-05

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

10 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06343376 2025-08-03

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Phase 1 Terminated

1 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03843294 2025-07-03

Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma

18 enrolled

Phase 1 Not yet recruiting

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse

NCT07024147 2025-06-17

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

20 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02303392 2025-06-10

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

34 enrolled 14 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00641381 2025-05-01

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

DermatologicLymphoidOther hematologic neoplasm

25 enrolled

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, HIV Infections, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02051257 2025-05-01

Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma

51 enrolled

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03939182 2025-04-25

Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05412290 2025-04-24

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05618366 2025-04-08

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

38 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT01497184 2025-03-13

Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood

95 enrolled

Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06464861 2025-02-07

CD19-CARNK/T

52 enrolled

Phase 1 Enrolling by invitation

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04488354 2025-01-10

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

36 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT06003179 2024-11-12

LOKI

Phase 1 Withdrawn

Lymphoma, Large B-Cell, Diffuse

NCT03450343 2024-10-28

Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma

9 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03955783 2024-10-26

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

78 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT03136497 2024-09-23

A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 1 Terminated

10 enrolled 14 charts

Lymphoma, Large B-Cell, Diffuse

NCT04450069 2024-08-20

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

18 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT06517004 2024-07-24

An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

9 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03892044 2024-05-02

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

7 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04995536 2024-04-25

CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL

Phase 1 Withdrawn